מדינה: מלטה
שפה: אנגלית
מקור: Medicines Authority
ROCURONIUM BROMIDE
N.V. Organon Kloosterstraat 6, NL-5349 AB Oss, Netherlands
M03AC09
ROCURONIUM BROMIDE 10 mg/ml
SOLUTION FOR INJECTION
ROCURONIUM BROMIDE 10 mg/ml
POM
MUSCLE RELAXANTS
Withdrawn
2006-04-18
PACKAGE LEAFLET: INFORMATION FOR THE USER ESMERON® 10 MG/ML SOLUTION FOR INJECTION ROCURONIUM BROMIDE READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU ARE GIVEN THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your anaesthetist or other doctor. • If you get any side effects, talk to your anaesthetist or other doctor. This includes any possible side effects not listed in this leaflet. See section 4. _ _ _WHAT IS IN THIS LEAFLET _ 1. What Esmeron is and what it is used for 2. What you need to know before Esmeron is given 3. How Esmeron is given 4. Possible side effects 5. How Esmeron is stored 6. Contents of the pack and other information 1. WHAT ESMERON IS AND WHAT IT IS USED FOR Esmeron is one of a group of drugs called _muscle relaxants_. Muscle relaxants are used during an operation as part of a general anaesthetic. When you have an operation your muscles must be completely relaxed. This makes it easier for the surgeon to perform the operation. Normally, your nerves send messages called _impulses _to your muscles. Esmeron acts by blocking these impulses so that your muscles relax. Because your breathing muscles also relax, you will need help to breathe (_artificial ventilation_) during and after your operation until you can breathe on your own again. During the operation your anaesthetist will keep a check on the effect of the muscle relaxant, and if necessary will give you some more. At the end of surgery, the effects of the drug are allowed to wear off and you will start breathing on your own. Sometimes the anaesthetist will give you another drug to help speed this up. Esmeron can also be used in Intensive Care Units to keep your muscles relaxed. 2. WHAT YOU NEED TO KNOW BEFORE ESMERON IS GIVEN YOU SHOULD NOT RECEIVE ESMERON • IF YOU ARE ALLERGIC (_hypersensitive_) to rocuronium, the bromide ion or any of the other ingredients of this medicine (listed in section 6). —> TELL YOUR ANAESTHETIST IF קרא את המסמך השלם
Page 1 of 13 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Esmeron® 10 mg/ml solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml Esmeron contains 10 mg rocuronium bromide. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection. pH: 3.8-4.2 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Esmeron is indicated in adult and paediatric patients (from term neonates to adolescents [0 to <18 years]) as an adjunct to general anaesthesia to facilitate tracheal intubation during routine sequence induction and to provide skeletal muscle relaxation during surgery. In adults Esmeron is also indicated to facilitate tracheal intubation during rapid sequence induction and as an adjunct in the intensive care unit (ICU) to facilitate intubation and mechanical ventilation. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Like other neuromuscular blocking agents, Esmeron should only be administered by, or under supervision of, experienced clinicians who are familiar with the action and use of these drugs. As with other neuromuscular blocking agents, the dosage of Esmeron should be individualised in each patient. The method of anaesthesia and the expected duration of surgery, the method of sedation and the expected duration of mechanical ventilation, the possible interaction with other drugs that are administered concomitantly, and the condition of the patient should be taken into account when determining the dose. The use of an appropriate neuromuscular monitoring technique is recommended for the evaluation of neuromuscular block and recovery. Inhalational anaesthetics do potentiate the neuromuscular blocking effects of Esmeron. This potentiation however, becomes clinically relevant in the course of anaesthesia, when the volatile agents have reached the tissue concentrations required for this interaction. Consequently, adjustments with Esmeron should be made by administering smaller maintenance doses at less frequent intervals or by using low קרא את המסמך השלם